Lantern Pharma Announces Preclinical Data In Pancreatic Cancer With Drug Candidate LP-184; Data Showed LP-184 Demonstrated Over 90% Pancreatic Tumor Shrinkage In In-Vivo Mouse Models In Eight Weeks
Lantern Pharma (NASDAQ:LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug